60 65 70 75 80 0 4 8 12 16 20 24 2.5 mg 5 mg 10 mg 0 5 10 15 20 0 4 8 12 16 20 24 2.5 mg 5 mg 10 mg 2.5 mg 13 13 13 13 13 13 13 12 5 mg 13 13 13 13 13 13 13 13 10 mg 13 13 13 13 13 12 12 12 In APEX U.S., the top two dose levels achieve meaningful vision gains of >10 letters by Week 4 and continue to improve over time, achieving a 20/25 Snellen visual acuity by Week 20 Mean ETDRS Letters Mean Change in BCVA over time Sample Size Observed BCVA over time Dose Level 2.5 mg 13 13 13 13 13 13 13 12 5 mg 13 13 13 13 13 13 13 13 10 mg 13 13 13 13 13 12 12 12 Sample Size Dose Level Mean ETDRS Letters +10.9 +13.4 +14.4 Weeks Weeks Final results of the APEX study in MESI. Includes patients in the per protocol set that completed the Week 4 visit and met all the eligibility criteria. Excludes one patient in the 5 mg dose that discontinued treatment before Week 4, and one patient in the 10 mg dose with a significant epiretinal membrane at baseline (exclusion criterion). One patient in the 10 mg dose level discontinued after Week 12 due to recurrent uveitis flare-up Mean Change 57